Hodgkin Lymphoma Following Adalimumab for the Treatment of Crohn’s Disease in an Adolescent

[1]  Á. Gutiérrez-Dalmau,et al.  Immunosuppressive Therapy and Malignancy in Organ Transplant Recipients , 2012, Drugs.

[2]  O. O’Connor,et al.  Targeting survival pathways in lymphoma. , 2010, Advances in experimental medicine and biology.

[3]  B. Sands,et al.  Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[4]  W. Bishop,et al.  Initial clinical experience with allopurinol‐thiopurine combination therapy in pediatric inflammatory bowel disease , 2008, Inflammatory bowel diseases.

[5]  A. Eggermont,et al.  TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. , 2006, The oncologist.

[6]  V. Annese,et al.  Usefulness of ω-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: A double-blind, randomized, placebo-controlled study , 2005 .

[7]  C. Brensinger,et al.  Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine , 2005, Gut.

[8]  V. Annese,et al.  Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double-blind, randomized, placebo-controlled study. , 2005, World journal of gastroenterology.

[9]  P. Macpherson,et al.  Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. , 2004, Blood.